Navigation Links
EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Date:5/30/2008

DURHAM, N.C., May 30 /PRNewswire/ -- Dr. George C. Clark of Xenobiotic Detection Systems (XDS) and Dr. Michael Denison at the University of California Davis, with support from the Superfund Basic Research Program, have developed a rapid and inexpensive recombinant cell bioassay system for the detection and relative quantification of dioxin-like chemicals. Dioxin-like chemicals are some of the most toxic chemicals known.

The CALUX(R) by XDS (Chemical Activated LUciferase Gene Expression) system has recently been published and is posted under "New Methods" on the SW-846 website. In March 2008, the EPA's Office of Solid Waste (OSW) Organic Methods Workgroup formally reviewed and approved Method 4435 for inclusion into Test Methods for Evaluating Solid Waste, Physical/Chemical Methods, also known as SW-846. The XDS-CALUX system consists of a unique sample processing method linked with a sensitive gene expression cell bioassay detection system providing unique sensitivity and selectivity for quantifying dioxin-like chemicals.

The XDS-CALUX(R) bioassay costs are 40%-70% lower than the traditional High Resolution Gas Chromatography/Mass Spectrometry (HR GC/MS) that was the old singular analysis standard. Xenobiotic Detection Systems Method 4435 provides an excellent screening tool to rapidly detect and quantify these ubiquitous and toxic environmental contaminants.

"This approval exemplifies the assay's versatility and is another major step for XDS," says President of XDS, Dr. George Clark. "Having been certified in the European Union since 2002 to primarily monitor feed and food it is wonderful to receive accreditation here in the U.S. Our screening analysis method is faster, far more affordable, and in many cases even more sensitive than the traditional HR GC/MS. The EPA's approval will allow us to better serve our clients and safeguard the environment from these toxic contaminants."

Research Institutes Worldwide using XDS-CALUX(R) Technology includes the United States: US FDA and University of California Davis. Asia: Hiyoshi Corporation of Japan, Cheng-Shiu University, Taiwan. Europe: Scientific Institute of Public Health, Brussels, Belgium, Federal Feed Laboratory, Tervuren, Belgium, and the National Veterinary Research Institute, Pulawy, Poland.

Development of the XDS-CALUX(R) technology was funded in part by Superfund Basic Research Program Grant (ES04699), and by Small Business Innovation Research Grants from the National Institute of Environmental Health Sciences (ES 08372-01 and ES 08372-02).

Additional information: XDS (http://www.dioxins.com) or call 1-888-D-I-O-X-I-N-S

(R) "Registered US Trademark and Patent Office"


'/>"/>
SOURCE Xenobiotic Detection Systems
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
(Date:6/24/2016)... ... 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located to ... vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat center ... as well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. The ...
Breaking Medicine News(10 mins):